» Articles » PMID: 38999301

Inotropic Agents: Are We Still in the Middle of Nowhere?

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Jul 13
PMID 38999301
Authors
Affiliations
Soon will be listed here.
Abstract

Inotropes are prescribed to enhance myocardial contractility while vasopressors serve to improve vascular tone. Although these medications remain a life-saving therapy in cardiovascular clinical scenarios with hemodynamic impairment, the paucity of evidence on these drugs makes the choice of the most appropriate vasoactive agent challenging. As such, deep knowledge of their pharmacological and hemodynamic effects becomes crucial to optimizing hemodynamic profile while reducing the potential adverse effects. Given this perspective, it is imperative for cardiologists to possess a comprehensive understanding of the underlying mechanisms governing these agents and to discern optimal strategies for their application across diverse clinical contexts. Thus, we briefly review these agents' pharmacological and hemodynamic properties and their reasonable clinical applications in cardiovascular settings. Critical interpretation of available data and the opportunities for future investigations are also highlighted.

References
1.
Tarvasmaki T, Lassus J, Varpula M, Sionis A, Sund R, Kober L . Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016; 20(1):208. PMC: 4931696. DOI: 10.1186/s13054-016-1387-1. View

2.
Mebazaa A, Motiejunaite J, Gayat E, Crespo-Leiro M, Lund L, Maggioni A . Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2017; 20(2):332-341. DOI: 10.1002/ejhf.991. View

3.
Bangash M, Kong M, Pearse R . Use of inotropes and vasopressor agents in critically ill patients. Br J Pharmacol. 2011; 165(7):2015-33. PMC: 3413841. DOI: 10.1111/j.1476-5381.2011.01588.x. View

4.
Fowler M, Laser J, Hopkins G, Minobe W, Bristow M . Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986; 74(6):1290-302. DOI: 10.1161/01.cir.74.6.1290. View

5.
Mortara A . Inotropes and vasopressors in acute heart failure, when the devil dresses as an angel. Eur J Heart Fail. 2017; 20(2):342-344. DOI: 10.1002/ejhf.1037. View